Functional: Nocturia: Difference between revisions

From UrologySchool.com
Jump to navigation Jump to search
 
(24 intermediate revisions by the same user not shown)
Line 1: Line 1:
== Background ==
== Background ==


* '''Definition of nocturia: voiding that is preceded and followed by sleep'''
* '''<span style="color:#ff0000">Definition of nocturia: voiding that is preceded and followed by sleep</span>'''
** '''Definition does not take into account the patient’s degree of bother'''
** '''<span style="color:#ff0000">≥2 voids per night appears to be clinically significant</span>'''
** '''≥2 voids per night appears to be clinically significant'''
**'''<span style="color:#ff0000">Definition does not take into account the patient’s degree of bother</span>'''
* Prevalence increases with age in both men and women
* Prevalence increases with age in both men and women
* '''Associated with:'''
* '''Associated with:'''
Line 20: Line 20:
== Diagnosis and Evaluation ==
== Diagnosis and Evaluation ==


=== '''UrologySchool.com Summary (2):''' ===
=== UrologySchool.com Summary (2): ===
#'''History and Physical Exam'''
#'''<span style="color:#ff0000">History and Physical Exam</span>'''
#'''Voiding diary or frequency-volume chart'''
#'''<span style="color:#ff0000">Voiding diary/frequency-volume chart</span>'''


=== History and Physical Exam ===
=== History and Physical Exam ===
Line 28: Line 28:
==== History ====
==== History ====
* '''Nocturia be a symptom of serious systemic illnesses including hypertension, diabetes, heart disease, and kidney disease'''
* '''Nocturia be a symptom of serious systemic illnesses including hypertension, diabetes, heart disease, and kidney disease'''
* '''Drug effects causing nocturia'''
* '''<span style="color:#ff0000">Drug effects causing nocturia</span>'''
** '''Increased urine output (5):'''
** '''<span style="color:#ff0000">Increased urine output (5):</span>'''
**# '''SSRIs''' (block antidiuretic hormone secretion)
**# '''SSRIs''' (block antidiuretic hormone secretion)
**# '''Tetracycline''' (attenuates antidiuretic hormone via decreases in cAMP accumulation and action)
**# '''Tetracycline''' (attenuates antidiuretic hormone via decreases in cAMP accumulation and action)
Line 35: Line 35:
**# '''Lithium (drug-induced nephrogenic diabetes insipidus)'''
**# '''Lithium (drug-induced nephrogenic diabetes insipidus)'''
**# '''Diuretics: timing of diuretic administration should be mid-afternoon''', to allow for elimination of lower extremity excess body fluid during normal waking hours. Men with nocturnal polyuria may benefit from diuretic therapy 6 hours before sleep
**# '''Diuretics: timing of diuretic administration should be mid-afternoon''', to allow for elimination of lower extremity excess body fluid during normal waking hours. Men with nocturnal polyuria may benefit from diuretic therapy 6 hours before sleep
** '''Insomnia and CNS effects'''
** '''<span style="color:#ff0000">Insomnia and CNS effects</span>'''
*** '''CNS stimulants''': dextroamphetamine, methylphenidate
*** '''CNS stimulants''': dextroamphetamine, methylphenidate
*** '''Antihypertensives''': α-Blockers, β-Blockers, methyldopa
*** '''Antihypertensives''': α-Blockers, β-Blockers, methyldopa
Line 44: Line 44:
*** '''Dopaminergic''' '''agonists:''' carbidopa
*** '''Dopaminergic''' '''agonists:''' carbidopa
*** '''Antiepileptics:''' phenytoin
*** '''Antiepileptics:''' phenytoin
** '''Direct lower urinary tract effects'''
** '''<span style="color:#ff0000">Direct lower urinary tract effects</span>'''
*** '''Ketamine''': direct bladder toxin
*** '''Ketamine''': direct bladder toxin
*** Tiaprofenic acid (Surgam): toxic cystitis
*** Tiaprofenic acid (Surgam): toxic cystitis
Line 50: Line 50:


==== Physical exam ====
==== Physical exam ====
* '''Peripheral edema''' resulting from cardiac disease, nephrotic syndrome, venous insufficiency
* '''<span style="color:#ff0000">Peripheral edema</span>''' resulting from cardiac disease, nephrotic syndrome, venous insufficiency
* '''Obesity and short neck may be suggestive of obstructive sleep apnea''' and be associated with nocturnal polyuria
* '''<span style="color:#ff0000">Obesity and short neck may be suggestive of obstructive sleep apnea</span>''' and be associated with nocturnal polyuria


=== Frequency-volume chart or a voiding diary ===
=== Voiding Diary/Frequency-volume chart ===
* '''The most useful tool in evaluating and classifying the cause of nocturia'''
* '''<span style="color:#ff0000">Most useful tool in evaluating and classifying the cause of nocturia</span>'''


== Etiology and Management ==
== Classification (3): ==


* '''Categorized as (3):'''
# '''<span style="color:#ff0000">Nocturnal polyuria: increased production of urine at night'''
*# '''Nocturnal polyuria: increased production of urine at night'''
# '''<span style="color:#ff0000">Decreased bladder capacity'''
*# '''Decreased bladder capacity'''
# '''<span style="color:#ff0000">Global polyuria'''
*# '''Global polyuria: 24-hour urine output > 40 ml/kg causing both daytime urinary frequency and nocturia'''


=== Nocturnal polyuria ===
== Nocturnal polyuria ==


=== Definitions ===
=== Definitions ===
* '''Nocturnal urine volume'''
* '''<span style="color:#ff0000">If nocturnal urine volume (3):'''
** '''>20%-33% of total 24-hr volume (age dependent)'''
** '''<span style="color:#ff0000">>20%-33% of total 24-hr volume (age dependent)'''
*** Normal circadian urine production is age dependent and '''the proportion of total urine output at night increases with age.'''
*** Normal circadian urine production is age dependent and '''the proportion of total urine output at night increases with age.'''
**** Age < 25: nocturnal urine volume/total = 14%
**** Age < 25: nocturnal urine volume/total = 14%
Line 75: Line 74:


=== Causes ===
=== Causes ===
'''Diuretics Can Over Do Evening Pee''' '''(6):'''
'''<span style="color:#0000ff">Diuretics Can Over Do Evening Pee (6):</span>'''
# '''Diuretics (depending on time of administration)'''
# '''<span style="color:#0000ff">D</span><span style="color:#ff0000">iuretics</span> (depending on time of administration)'''
# '''Congestive heart failure'''
# '''<span style="color:#0000ff">C</span><span style="color:#ff0000">ongestive heart failure</span>'''
# '''Obstructive sleep apnea'''
# '''<span style="color:#0000ff">O</span><span style="color:#ff0000">bstructive sleep apnea</span>'''
#* Defined as the sudden cessation of respiration during sleep because of airway obstruction
#* Defined as the sudden cessation of respiration during sleep because of airway obstruction
#** Increased airway pressures lead to '''hypoxia''', which in turn causes pulmonary vasoconstriction, the latter leading to increased right atrial transmural pressure with '''resulting increase in ANP''' production and ultimately increased renal sodium and water excretion
#** Increased airway pressures lead to '''hypoxia''', which in turn causes pulmonary vasoconstriction, the latter leading to increased right atrial transmural pressure with '''resulting increase in ANP''' production and ultimately increased renal sodium and water excretion
#* '''Common cause of nocturnal polyuria;'''
#* '''<span style="color:#ff0000">Common cause of nocturnal polyuria</span>'''
# '''Diabetes mellitus'''
# '''<span style="color:#0000ff">D</span><span style="color:#ff0000">iabetes mellitus</span>'''
# '''Excessive nighttime fluid intake'''
# '''<span style="color:#0000ff">E</span><span style="color:#ff0000">xcessive nighttime fluid intake</span>'''
# '''Peripheral edema'''
# '''<span style="color:#0000ff">P</span><span style="color:#ff0000">eripheral edema</span>'''


=== Management ===
=== Management ===
* '''Treat underlying contributing medical comorbidities'''
* '''<span style="color:#ff0000">Treat underlying contributing medical comorbidities'''
** Treating sleep disturbances, hypertension, and obesity may decrease the number of nightly voids and improve quality of life
** Treating sleep disturbances, hypertension, and obesity may decrease the number of nightly voids and improve quality of life
** '''Treating sleep apnea with continuous positive airway pressure (CPAP) can improve nocturia'''
** '''<span style="color:#ff0000">Treating sleep apnea with continuous positive airway pressure (CPAP) can improve nocturia</span>'''
* '''Conservative management: cessation of fluid intake 4 hours before bedtime,''' compressive lower extremity stockings and/or administration of diuretics in the mid-afternoon for edema states, and antidiuretic therapy at bedtime
* '''<span style="color:#ff0000">Conservative management (3)</span>'''
* '''Medical management (2):'''
*#'''<span style="color:#ff0000">Cessation of fluid intake 4 hours before bedtime</span>'''
*# '''Demopressin'''
*#'''<span style="color:#ff0000">Compressive lower extremity stockings</span>'''
*#* '''Mechanism of action: binds to V2 receptors in the renal collecting tubules, resulting in increased water permeability, enhanced water reabsorption,''' diluted extracellular fluid, and concentrated urine.
*#'''<span style="color:#ff0000">Administration of diuretics in the mid-afternoon for edema states</span>'''
*#* '''Adverse events:'''
* '''<span style="color:#ff0000">Medical management (2):</span>'''
*#** '''Hyponatremia'''
*# '''<span style="color:#ff0000">Demopressin (</span><span style="color:#ff0000">antidiuretic therapy at bedtime</span><span style="color:#ff0000">)</span>'''
*#* '''<span style="color:#ff0000">Mechanism of action: binds to V2 receptors in the renal collecting tubules, resulting in increased water permeability, enhanced water reabsorption,''' diluted extracellular fluid, and concentrated urine.
*#* '''<span style="color:#ff0000">Adverse events:</span>'''
*#** '''<span style="color:#ff0000">Hyponatremia</span>'''
*#*** '''Risk is <1% in those age < 65 and 8% in those age > 65'''
*#*** '''Risk is <1% in those age < 65 and 8% in those age > 65'''
*#* '''Contraindications:'''
*#* '''Contraindications:'''
Line 117: Line 119:
*#**** '''Salt losing nephropathies'''
*#**** '''Salt losing nephropathies'''
*#* '''There appears to be a lower risk of hyponatremia in patients with the nasal spray as opposed to oral preparations.'''  
*#* '''There appears to be a lower risk of hyponatremia in patients with the nasal spray as opposed to oral preparations.'''  
*#* '''Dosing of desmopressin melt'''
*#* '''<span style="color:#ff0000">Dosing of desmopressin melt</span>'''
*#** '''Women are more sensitive to demopression''' in terms of effects on nocturnal urine production and duration of action; '''50 μg of desmopressin melt may be the lowest therapeutically beneficial dose for men while women do well with 25 μg'''
*#** '''<span style="color:#ff0000">Females are more sensitive to demopressin</span>''' in terms of effects on nocturnal urine production and duration of action;  
*#* '''Monitoring'''
*#***'''50 μg of desmopressin melt may be the lowest therapeutically beneficial dose for males while females do well with a lower dose of 25 μg'''
*#** '''Obtain a baseline serum sodium before initiating therapy'''
*#* '''<span style="color:#ff0000">Monitoring</span>'''
*#** '''Monitor the serum sodium within 7 days and then 28 days after initial or incremental dosing, then continue to check sodium levels every 6 months (or more often as indicated).'''
*#** '''<span style="color:#ff0000">Obtain a baseline serum sodium before initiating therapy</span>'''
*# '''Imipramine'''
*#** '''<span style="color:#ff0000">Monitor the serum sodium within 7 days and then 28 days after initial or incremental dosing, then continue to check sodium levels every 6 months</span> (or more often as indicated).'''
*#* '''MOA: a tricyclic antidepressant''' with a complex pharmacologic profile including:
*# '''<span style="color:#ff0000">Imipramine</span>'''
*#* '''<span style="color:#ff0000">MOA: a tricyclic antidepressant</span>''' with a complex pharmacologic profile including:
*#** Nonsubtype-selective '''antimuscarinic effect'''
*#** Nonsubtype-selective '''antimuscarinic effect'''
*#** Effects in '''modulating vasopressin release'''
*#** Effects in '''modulating vasopressin release'''
Line 129: Line 132:
*#* '''Adverse events:'''
*#* '''Adverse events:'''
*#** '''Arrythmia, should be used with caution'''
*#** '''Arrythmia, should be used with caution'''
*#*** '''H'''as been shown to prolong the PR, QRS, and QTc intervals, increase heart rate, and lower T-wave amplitude during a 4-week treatment course. There have been rare reports of '''torsades de pointes and sudden death resulting from imipramine administration'''
*#*** Has been shown to prolong the PR, QRS, and QTc intervals, increase heart rate, and lower T-wave amplitude during a 4-week treatment course. There have been rare reports of '''torsades de pointes and sudden death resulting from imipramine administration'''


=== Decreased bladder capacity ===
== Decreased Bladder Capacity ==


* '''Can result from either a global decrease in bladder capacity as expressed by a low maximum voided volume or simply a decrease in nocturnal bladder capacity.''' In both instances, nocturnal urine volume exceeds nocturnal bladder capacity and the patient awakens because of the need to void.
=== Definitions ===
** '''Maximum voided volume (MVV): the largest single voided volume in a 24-hr period'''
*'''<span style="color:#ff0000">Nocturnal urine volume exceeds nocturnal bladder capacity and the patient awakens because of the need to void</span>'''
** '''Nocturnal urine volume (NUV): Total volume of urine passed during the night, including the first morning void'''
**'''<span style="color:#ff0000">Can result from either a (2)</span>'''
* '''The nocturnal bladder capacity index (NBCi) is a useful means to examine the relationship between the patient’s own bladder capacity and nocturnal voided volumes during a 24-hour period.'''
**#'''<span style="color:#ff0000">Global decrease in bladder capacity, as expressed by a low maximum voided volume (MVV)</span>'''  
** '''NBCi = (ANV − PNV)'''
**#*'''Maximum voided volume (MVV): the largest single voided volume in a 24-hr period'''
**# '''Nighttime frequency or actual number of nightly voids (ANV): The number of voids recorded from the time the individual goes to bed with the intention of sleeping, to the time the individual wakes with the intention of rising'''
**#'''<span style="color:#ff0000">Simply a decrease in nocturnal bladder capacity i.e. small nocturnal bladder capacity, as expressed by a nocturnal bladder capacity index (NBCi) > 0</span>'''
**# '''PNV = (Ni − 1)'''
* '''Nocturnal bladder capacity index (NBCi)'''
**#* '''Nocturia index (Ni) = NUV/MVV; when Ni > 1 NUV nocturia or enuresis occurs because functional bladder capacity (MVV) is exceeded'''
**'''Useful means to examine the relationship between the patient’s own bladder capacity and nocturnal voided volumes during a 24-hour period.'''
** '''If NBCi is greater than 0, then nocturia occurs at volumes less than MVV i.e. small nocturnal bladder capacity'''
** '''NBCi = Actual number of nightly voids (ANV) Predicted number of nightly voids (PNV)'''
*** '''Actual number of nightly voids (ANV) or nighttime frequency: number of voids recorded from the time the individual goes to bed with the intention of sleeping, to the time the individual wakes with the intention of rising'''
*** '''Predicted number of nightly voids (PNV) = (Nocturia Index (NI) − 1)'''
**** '''Nocturia index (Ni) = Nocturnal urine volume (NUV)/Maximum voided volume (MVV)'''
*****'''Nocturnal urine volume (NUV): Total volume of urine passed during the night, including the first morning void'''
*****'''If Ni > 1, nocturia or enuresis occurs because functional bladder capacity (MVV) is exceeded'''
** '''If NBCi > 0, nocturia occurs at volumes less than MVV i.e. small nocturnal bladder capacity'''
** Example: a patient who voids 8 times per night (ANV = 8), who voids a total of 800 mL during the intended hours of sleep (NUV = 800 mL), and who has an MVV of 200 mL would have an Ni of 4 (Ni = NUV/MVV = 800 mL/200 mL = 4). This patient’s PNV = Ni − 1 = 4 − 1 = 3. Therefore this patient’s NBCi = ANV − PNV = 8 − 3 = 5. An NBCi of 5 indicates a substantially diminished nocturnal bladder capacity
** Example: a patient who voids 8 times per night (ANV = 8), who voids a total of 800 mL during the intended hours of sleep (NUV = 800 mL), and who has an MVV of 200 mL would have an Ni of 4 (Ni = NUV/MVV = 800 mL/200 mL = 4). This patient’s PNV = Ni − 1 = 4 − 1 = 3. Therefore this patient’s NBCi = ANV − PNV = 8 − 3 = 5. An NBCi of 5 indicates a substantially diminished nocturnal bladder capacity


* '''Causes (11):'''
=== Causes (11): ===
*# '''Ureteral calculi'''
# '''Ureteral calculi'''
*# '''Bladder calculi'''
# '''Bladder calculi'''
*# '''Cystitis''' (bacterial, interstitial, tuberculous, radiation)
# '''Cystitis''' (bacterial, interstitial, tuberculous, radiation)
*# '''Cancer''' of the bladder, prostate, or urethra
# '''Cancer''' of the bladder, prostate, or urethra
*# '''Bladder outlet obstruction'''
# '''Bladder outlet obstruction'''
*# '''Neurogenic bladder'''
# '''Neurogenic bladder'''
*# '''Low bladder compliance'''
# '''Low bladder compliance'''
*# '''Drugs''' '''such as xanthines (caffeine, theophylline) and β-blockers'''
# '''Medications''' '''such as xanthines (caffeine, theophylline) and β-blockers'''
*# '''Idiopathic nocturnal detrusor overactivity'''
# '''Idiopathic nocturnal detrusor overactivity'''
*# '''Anxiety disorders'''
# '''Anxiety disorders'''
*# '''Learned voiding dysfunction'''
# '''Learned voiding dysfunction'''
* '''Treatment directed at underlying cause'''
 
=== Management ===
 
*'''Directed at underlying cause'''
** '''Phytotherapies'''
** '''Phytotherapies'''
*** '''Pygeum africanum and cernilton are associated with improvement in nocturia'''
*** '''Pygeum africanum and cernilton are associated with improvement in nocturia'''
Line 171: Line 183:
**** '''TURP appears to be superior to tamsulosin for treatment of BPH-related nocturia'''
**** '''TURP appears to be superior to tamsulosin for treatment of BPH-related nocturia'''


=== Global polyuria ===
== Global polyuria ==
 
=== Definition ===
 
* '''<span style="color:#ff0000">24-hour urine output > 40 ml/kg causing both daytime urinary frequency and nocturia</span>'''
 
=== Causes (3): ===
# '''<span style="color:#ff0000">Primary polydipsia (dipsogenic (damage to thirst mechanism in hypothalamus) and psychogenic)</span>'''
# '''<span style="color:#ff0000">Diabetes mellitus</span>'''
# '''<span style="color:#ff0000">Diabetes insipidus</span>'''


* '''Causes (3):'''
==== Diabetes Insipidus ====
*# '''Primary polydipsia (dipsogenic (damage to thirst mechanism in hypothalamus) and psychogenic)'''
*Disorder of water balance
*# '''Diabetes mellitus'''
*'''Inappropriate excretion of water leads to polydipsia in an effort to prevent circulatory collapse'''
*# '''Diabetes insipidus'''
* '''Classified (2): central vs. nephrogenic'''
*#* Disorder of water balance in which '''inappropriate excretion of water leads to polydipsia in an effort to prevent circulatory collapse.'''
** '''Central diabetes insipidus occurs when there is deficiency in ADH (synthesis or secretion)'''
*#* '''Can be central or nephrogenic:'''
*** Can be due to loss of neurosecretory neurons in the hypothalamus or the posterior pituitary gland as a result of trauma, primary pituitary tumors (e.g., craniopharyngioma), metastatic disease (e.g., breast, lung), infiltrative diseases (e.g., sarcoid), infarction (e.g., Sheehan syndrome postpartum), or infection (e.g., tuberculosis, meningitis) or can be idiopathic.
*#** '''Central diabetes insipidus occurs when there is deficiency in ADH (synthesis or secretion)'''
** '''Nephrogenic diabetes insipidus occurs when there is normal ADH levels but the kidneys do not respond appropriately to the hormone'''
*#*** Can be due to loss of neurosecretory neurons in the hypothalamus or the posterior pituitary gland as a result of trauma, primary pituitary tumors (e.g., craniopharyngioma), metastatic disease (e.g., breast, lung), infiltrative diseases (e.g., sarcoid), infarction (e.g., Sheehan syndrome postpartum), or infection (e.g., tuberculosis, meningitis) or can be idiopathic.
*** Can be due to chronic kidney disease
*#** '''Nephrogenic diabetes insipidus occurs when there is normal ADH levels but the kidneys do not respond appropriately to the hormone'''
*#*** Can be due to chronic kidney disease


== Questions ==
== Questions ==

Latest revision as of 07:52, 11 February 2024

Background[edit | edit source]

  • Definition of nocturia: voiding that is preceded and followed by sleep
    • ≥2 voids per night appears to be clinically significant
    • Definition does not take into account the patient’s degree of bother
  • Prevalence increases with age in both men and women
  • Associated with:
    1. Decreased survival
    2. Decreased quality of life
    3. Decreased sleep efficiency and sleep latency
      • Sleep efficiency: actual time asleep (minutes) divided by total time of intended sleep (minutes); normal > 85%
      • Sleep latency: time it takes to go from being completely awake to being completely asleep
      • Sleep loss can negatively affect health by decreasing immune function, increasing the risk for cardiovascular disease, obesity and type 2 diabetes
    4. Increased prevalence of depressive symptoms
    5. Increased risk for metabolic syndrome
    6. Increased risk of falls
    7. Increased impairment in work and non-work activities
  • Factors that inhibit ADH and cause diuresis (inhibit water reabsorption) include prostaglandin E2, ANP, hypercalcemia, hypokalemia, lithium, and tetracyclines.

Diagnosis and Evaluation[edit | edit source]

UrologySchool.com Summary (2):[edit | edit source]

  1. History and Physical Exam
  2. Voiding diary/frequency-volume chart

History and Physical Exam[edit | edit source]

History[edit | edit source]

  • Nocturia be a symptom of serious systemic illnesses including hypertension, diabetes, heart disease, and kidney disease
  • Drug effects causing nocturia
    • Increased urine output (5):
      1. SSRIs (block antidiuretic hormone secretion)
      2. Tetracycline (attenuates antidiuretic hormone via decreases in cAMP accumulation and action)
      3. Calcium channel blockers (increases atrial natriuretic peptide, blocks sodium reabsorption in proximal convoluted tubule)
      4. Lithium (drug-induced nephrogenic diabetes insipidus)
      5. Diuretics: timing of diuretic administration should be mid-afternoon, to allow for elimination of lower extremity excess body fluid during normal waking hours. Men with nocturnal polyuria may benefit from diuretic therapy 6 hours before sleep
    • Insomnia and CNS effects
      • CNS stimulants: dextroamphetamine, methylphenidate
      • Antihypertensives: α-Blockers, β-Blockers, methyldopa
      • Respiratory: albuterol, theophylline
      • Decongestants: phenylephrine, pseudoephedrine
      • Hormones: corticosteroids, thyroid
      • Psychotropics: MAOIs, SSRIs, atypical antidepressants
      • Dopaminergic agonists: carbidopa
      • Antiepileptics: phenytoin
    • Direct lower urinary tract effects
      • Ketamine: direct bladder toxin
      • Tiaprofenic acid (Surgam): toxic cystitis
      • Cyclophosphamide

Physical exam[edit | edit source]

  • Peripheral edema resulting from cardiac disease, nephrotic syndrome, venous insufficiency
  • Obesity and short neck may be suggestive of obstructive sleep apnea and be associated with nocturnal polyuria

Voiding Diary/Frequency-volume chart[edit | edit source]

  • Most useful tool in evaluating and classifying the cause of nocturia

Classification (3):[edit | edit source]

  1. Nocturnal polyuria: increased production of urine at night
  2. Decreased bladder capacity
  3. Global polyuria

Nocturnal polyuria[edit | edit source]

Definitions[edit | edit source]

  • If nocturnal urine volume (3):
    • >20%-33% of total 24-hr volume (age dependent)
      • Normal circadian urine production is age dependent and the proportion of total urine output at night increases with age.
        • Age < 25: nocturnal urine volume/total = 14%
        • Age > 65: nocturnal urine volume/total = 34%
    • >6.4 mL/kg
    • >54 mL/hr

Causes[edit | edit source]

Diuretics Can Over Do Evening Pee (6):

  1. Diuretics (depending on time of administration)
  2. Congestive heart failure
  3. Obstructive sleep apnea
    • Defined as the sudden cessation of respiration during sleep because of airway obstruction
      • Increased airway pressures lead to hypoxia, which in turn causes pulmonary vasoconstriction, the latter leading to increased right atrial transmural pressure with resulting increase in ANP production and ultimately increased renal sodium and water excretion
    • Common cause of nocturnal polyuria
  4. Diabetes mellitus
  5. Excessive nighttime fluid intake
  6. Peripheral edema

Management[edit | edit source]

  • Treat underlying contributing medical comorbidities
    • Treating sleep disturbances, hypertension, and obesity may decrease the number of nightly voids and improve quality of life
    • Treating sleep apnea with continuous positive airway pressure (CPAP) can improve nocturia
  • Conservative management (3)
    1. Cessation of fluid intake 4 hours before bedtime
    2. Compressive lower extremity stockings
    3. Administration of diuretics in the mid-afternoon for edema states
  • Medical management (2):
    1. Demopressin (antidiuretic therapy at bedtime)
      • Mechanism of action: binds to V2 receptors in the renal collecting tubules, resulting in increased water permeability, enhanced water reabsorption, diluted extracellular fluid, and concentrated urine.
      • Adverse events:
        • Hyponatremia
          • Risk is <1% in those age < 65 and 8% in those age > 65
      • Contraindications:
        • Campbell’s: Elderly patients (>65 years) with baseline hyponatremia
        • Product monograph:
          • Patients with type IIB or platelet-type (pseudo) Willerbrand disease, because of the risk of platelet aggregation and thrombocytopenia
          • Any condition associated with impaired water excretion, such as:
            • Hyponatremia
            • Severe liver disease
            • Nephrosis
            • Cardiac insufficiency
            • Chronic renal insufficiency
            • Congestive heart failure
            • Habitual or psychogenic polydypsia
          • Any medical conditions which lead to sodium losing states such as:
            • Vomiting
            • Diarrhoea
            • Bulimia
            • Anorexia nervosa
            • Adrenocortical insufficiency
            • Salt losing nephropathies
      • There appears to be a lower risk of hyponatremia in patients with the nasal spray as opposed to oral preparations.
      • Dosing of desmopressin melt
        • Females are more sensitive to demopressin in terms of effects on nocturnal urine production and duration of action;
          • 50 μg of desmopressin melt may be the lowest therapeutically beneficial dose for males while females do well with a lower dose of 25 μg
      • Monitoring
        • Obtain a baseline serum sodium before initiating therapy
        • Monitor the serum sodium within 7 days and then 28 days after initial or incremental dosing, then continue to check sodium levels every 6 months (or more often as indicated).
    2. Imipramine
      • MOA: a tricyclic antidepressant with a complex pharmacologic profile including:
        • Nonsubtype-selective antimuscarinic effect
        • Effects in modulating vasopressin release
        • Potentiating renal proximal tubular sodium and water reabsorption
      • Adverse events:
        • Arrythmia, should be used with caution
          • Has been shown to prolong the PR, QRS, and QTc intervals, increase heart rate, and lower T-wave amplitude during a 4-week treatment course. There have been rare reports of torsades de pointes and sudden death resulting from imipramine administration

Decreased Bladder Capacity[edit | edit source]

Definitions[edit | edit source]

  • Nocturnal urine volume exceeds nocturnal bladder capacity and the patient awakens because of the need to void
    • Can result from either a (2)
      1. Global decrease in bladder capacity, as expressed by a low maximum voided volume (MVV)
        • Maximum voided volume (MVV): the largest single voided volume in a 24-hr period
      2. Simply a decrease in nocturnal bladder capacity i.e. small nocturnal bladder capacity, as expressed by a nocturnal bladder capacity index (NBCi) > 0
  • Nocturnal bladder capacity index (NBCi)
    • Useful means to examine the relationship between the patient’s own bladder capacity and nocturnal voided volumes during a 24-hour period.
    • NBCi = Actual number of nightly voids (ANV) − Predicted number of nightly voids (PNV)
      • Actual number of nightly voids (ANV) or nighttime frequency: number of voids recorded from the time the individual goes to bed with the intention of sleeping, to the time the individual wakes with the intention of rising
      • Predicted number of nightly voids (PNV) = (Nocturia Index (NI) − 1)
        • Nocturia index (Ni) = Nocturnal urine volume (NUV)/Maximum voided volume (MVV)
          • Nocturnal urine volume (NUV): Total volume of urine passed during the night, including the first morning void
          • If Ni > 1, nocturia or enuresis occurs because functional bladder capacity (MVV) is exceeded
    • If NBCi > 0, nocturia occurs at volumes less than MVV i.e. small nocturnal bladder capacity
    • Example: a patient who voids 8 times per night (ANV = 8), who voids a total of 800 mL during the intended hours of sleep (NUV = 800 mL), and who has an MVV of 200 mL would have an Ni of 4 (Ni = NUV/MVV = 800 mL/200 mL = 4). This patient’s PNV = Ni − 1 = 4 − 1 = 3. Therefore this patient’s NBCi = ANV − PNV = 8 − 3 = 5. An NBCi of 5 indicates a substantially diminished nocturnal bladder capacity

Causes (11):[edit | edit source]

  1. Ureteral calculi
  2. Bladder calculi
  3. Cystitis (bacterial, interstitial, tuberculous, radiation)
  4. Cancer of the bladder, prostate, or urethra
  5. Bladder outlet obstruction
  6. Neurogenic bladder
  7. Low bladder compliance
  8. Medications such as xanthines (caffeine, theophylline) and β-blockers
  9. Idiopathic nocturnal detrusor overactivity
  10. Anxiety disorders
  11. Learned voiding dysfunction

Management[edit | edit source]

  • Directed at underlying cause
    • Phytotherapies
      • Pygeum africanum and cernilton are associated with improvement in nocturia
    • Medical therapy
      • α-blockers, 5-ARIs, antimuscarinics, and antimuscarinics plus α-blockers have occasionally been found to have a statistically significant reduction in nocturia episodes, but clinical significance appears to be minimal.
      • When 5-ARIs and α-blockers are used in combination, they have the same degree of success as α-blockers alone
      • The optimal patients to treat with medications that target the bladder and the prostate appear to be those who have a large number of nocturia episodes (mostly resulting from severe urgency)
    • Surgery
      • Patients with high-pressure urinary retention causing nocturnal enuresis are treated by initial catheterization to relieve the pressure, followed by appropriate assessment with a view to using endoscopic surgery to resect, vaporize, or enucleate the prostate, or open removal of the prostate
        • Treating bladder outlet obstruction is thought to improve nocturia by:
          • Lowering postvoid residual volume
          • Increasing functional bladder capacity
          • Reducing urinary frequency
        • TURP appears to be superior to tamsulosin for treatment of BPH-related nocturia

Global polyuria[edit | edit source]

Definition[edit | edit source]

  • 24-hour urine output > 40 ml/kg causing both daytime urinary frequency and nocturia

Causes (3):[edit | edit source]

  1. Primary polydipsia (dipsogenic (damage to thirst mechanism in hypothalamus) and psychogenic)
  2. Diabetes mellitus
  3. Diabetes insipidus

Diabetes Insipidus[edit | edit source]

  • Disorder of water balance
  • Inappropriate excretion of water leads to polydipsia in an effort to prevent circulatory collapse
  • Classified (2): central vs. nephrogenic
    • Central diabetes insipidus occurs when there is deficiency in ADH (synthesis or secretion)
      • Can be due to loss of neurosecretory neurons in the hypothalamus or the posterior pituitary gland as a result of trauma, primary pituitary tumors (e.g., craniopharyngioma), metastatic disease (e.g., breast, lung), infiltrative diseases (e.g., sarcoid), infarction (e.g., Sheehan syndrome postpartum), or infection (e.g., tuberculosis, meningitis) or can be idiopathic.
    • Nephrogenic diabetes insipidus occurs when there is normal ADH levels but the kidneys do not respond appropriately to the hormone
      • Can be due to chronic kidney disease

Questions[edit | edit source]

  1. What is the definition of nocturia?
  2. How many episodes of nocturia are considered clinically significant?
  3. List medications associated with nocturia
  4. Which characteristics on physical exam are associated with nocturia?
  5. How are the causes of nocturia categorized?
  6. What are 2 definitions of nocturnal polyuria?
  7. What are the causes of nocturnal polyuria?
  8. What is the potential medications used to treat nocturnal polyuria? What is their mechanism of action? What is the most serious potential adverse events related to their use?
  9. Describe your approach to prescribing desmopressin
  10. List causes of reduced bladder capacity
  11. What is the definition of global polyuria
  12. List causes of global polyuria

Answers[edit | edit source]

  1. What is the definition of nocturia?
    • Voiding preceded and followed by sleep
  2. How many episodes of nocturia are considered clinically significant?
    • ≥2

References[edit | edit source]

  • Wein AJ, Kavoussi LR, Partin AW, Peters CA (eds): CAMPBELL-WALSH UROLOGY, ed 11. Philadelphia, Elsevier, 2015, chap 78